Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans
Open Access
- 9 February 2021
- journal article
- research article
- Published by Wiley in JCSM Rapid Communications
- Vol. 4 (2) , 232-244
Abstract
Background: Monoclonal antibody (mAb) immune checkpoint inhibitor (ICI) therapies have dramatically impacted oncology this past decade. However, only about one‐third of patients respond to treatment, and biomarkers to predict responders are lacking. Recent ICI clinical pharmacology data demonstrate high baseline drug clearance (CL0) significantly associates with shorter overall survival, independent of ICI exposure, in patients receiving ICI mAb therapies. This suggests CL0 may predict outcomes from ICI therapy, and cachectic signalling may link elevated CL0 and poor response. Our aim was to determine if mouse models of cancer cachexia will be useful for studying these phenomena and their underlying mechanisms.Methods: We evaluated pembrolizumab CL in the C26 and Lewis lung carcinoma mouse models of cancer cachexia. A single treatment of vehicle or pembrolizumab, at a dose of 2 or 10 mg/kg, was administered intravenously by tail vein injection. Pembrolizumab was quantified by an ELISA in serial plasma samples, and FcRn gene (Fcgrt) expression was assessed in liver using real‐time quantitative reverse transcription PCR. Non‐compartmental and mixed‐effects pharmacokinetics analyses were performed.Results: We observed higher pembrolizumab CL0 and decreased Fcgrt expression in whole liver tissue from tumour‐bearing vs. tumour‐free mice. In multivariate analysis, presence of tumour, total murine IgG, muscle weight and Fcgrt expression were significant covariates on CL, and total murine IgG was a significant covariate on V1 and Q.Conclusions: These data demonstrate increases in catabolic clearance of monoclonal antibodies observed in humans can be replicated in cachectic mice, in which Fcgrt expression is also reduced. Notably, FcRn activity is essential for proper antigen presentation and antitumour immunity, which may permit the study of cachexia's impact on FcRn‐mediated clearance and efficacy of ICI therapies.Keywords
This publication has 51 references indexed in Scilit:
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialThe Lancet, 2014
- The Role of FcRn in Antigen PresentationFrontiers in Immunology, 2014
- Quantitative cumulative biodistribution of antibodies in micemAbs, 2014
- The effect of the neonatal Fc receptor on human IgG biodistribution in micemAbs, 2014
- Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal CancerImmunity, 2013
- Immunological Variation Between Inbred Laboratory Mouse StrainsVeterinary Pathology, 2011
- Population Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- β2-Microglobulin Deficient Mice Catabolize IgG More Rapidly Than FcRn-α-Chain Deficient MiceExperimental Biology and Medicine, 2008
- The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its LifespanJournal of Experimental Medicine, 2003